BeiGene, Ltd.
Anti-TIGIT antibodies and their use as therapeutics and diagnostics

Last updated:

Abstract:

Provided are antibodies that specifically bind to TIGIT (T cell immunoreceptor with Ig and ITIM domains, WUCAM or Vstm3) and inhibit Tigit-mediated cellular signaling and activities in immune cells. The anti-TIGIT antibodies can be used to treat or diagnose cancer, infectious diseases or other pathological disorders that may be modulated by Tigit-mediated functions.

Status:
Grant
Type:

Utility

Filling date:

29 Dec 2018

Issue date:

4 Jan 2022